Butterfly Network, Inc. (BFLY) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Butterfly Network, Inc. is a digital health company developing portable, semiconductor-based ultrasound technology (Ultrasound-on-Chip) for point-of-care imaging. The company operates as a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $21.5 million | $18.5 million | $39.1 million | $34.0 million |
| Gross Profit | $12.6 million | $10.9 million | $22.9 million | $20.0 million |
| Gross Margin | 58.6% | 59.1% | 58.4% | 58.9% |
| Net Loss | $(15.7) million | $(28.7) million | $(37.5) million | $(62.2) million |
| Operating Cash Flow | N/A | N/A | $(30.7) million | $(69.7) million |
| Cash & Equivalents | $102.1 million | $134.4 million (Dec 2023) | As of June 30, 2024 | |
| Debt | None | None | No floating rate debt; minimal interest expense. |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16.2% year-over-year (YoY) in Q2 2024. Product revenue grew 19.4% driven by the launch of the iQ3 probe and international expansion, while software revenue grew 10.1%.
- Expense Reduction: Operating expenses decreased significantly due to cost-cutting measures initiated in 2023.
- R&D: Decreased 39.8% YoY to $9.4 million, primarily due to personnel reductions.
- G&A: Decreased 31.3% YoY to $10.1 million, driven by lower stock-based compensation and legal fees.
- Other Expenses: Decreased 72.1% YoY to $0.6 million, reflecting the non-recurrence of prior-year severance and litigation costs.
- Loss Narrowing: Net loss improved by 45.2% YoY to $15.7 million, reflecting both revenue growth and substantial expense management.
- Units Fulfilled: Increased 3.6% YoY, with international volume more than doubling.
Guidance, Outlook, and Risks
- Liquidity Runway: Management expects cash reserves of $102.1 million to fund operations into 2027. The company aims to raise capital before reaching 2027 to achieve profitability, prioritizing non-dilutive sources (grants/debt) before equity.
- Cost Optimization: A new partnership announced in July 2024 aims to optimize technical functions, targeting $10 million in annual cost savings. Transition costs of approximately $3.5 million are expected in the second half of 2024.
- Revenue Mix: Software and other services mix decreased to 31.8% in Q2 2024 (from 33.6% in Q2 2023) due to the higher selling price of the new iQ3 device. Management expects this mix to remain flat or decrease in 2024.
- Risks:
- Litigation: Ongoing class action and derivative lawsuits regarding the 2021 business combination and financial disclosures. Outcomes are uncertain, and losses cannot be reasonably estimated.
- Capital Needs: Continued reliance on external financing to reach profitability.
- Regulatory: Dependence on maintaining regulatory approvals for medical devices.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $102.1 million cash balance against the projected runway to 2027, considering the new $3.5 million transition costs.
- Revenue Quality: Assess the sustainability of the 19.4% product revenue growth, noting the exclusion of large, non-recurring medical school deployments from the prior year.
- Legal Exposure: Monitor developments in the Rose v. Butterfly Network and derivative lawsuits for potential material financial impact.
- Software Mix: Track the shift in revenue mix toward hardware (iQ3) versus recurring software subscriptions, as long-term valuation often hinges on SaaS growth.
- Inventory Commitments: Review the $10.3 million in minimum inventory purchase commitments and the risk of obsolescence given the company's sales history.